Brief: RedHill Biopharma Advances Its Groundbreaking Late-Stage Crohn's Disease Program Building On Statistically Significant Positive Rhb-104 Phase 3 Result
12/03/2025 11:08
March 12 (Reuters) - Redhill Biopharma Ltd 2RHy.F: REDHILL BIOPHARMA ADVANCES ITS GROUNDBREAKING LATE-STAGE CROHN'S DISEASE PROGRAM BUILDING ON STATISTICALLY SIGNIFICANT POSITIVE RHB-104 PHASE 3 RESULT Source text: ID:nPnwV42Ma Further company coverage: [2RHy.F] ((Reuters.Briefs@thomsonreuters.com;))